Goat IgG anti-Human IgA-FITC, MinX none

Catalog Number: DNA-SEC-183015
Article Name: Goat IgG anti-Human IgA-FITC, MinX none
Biozol Catalog Number: DNA-SEC-183015
Supplier Catalog Number: SEC-183015
Alternative Catalog Number: DNA-SEC-183015
Manufacturer: dianova
Host: Goat
Category: Antikörper
Application: FLISA,FACS,IF
Species Reactivity: Human
Immunogen: Human IgA alpha heavy chain
Conjugation: FITC
Alternative Names: goat anti-Human IgA (alpha chain) fluorescein conjugated Antibody, goat anti-Human IgA alpha Antibody FITC conjugation
Format: IgG
Target Specificity: IgA
Cross-Adsorption (MinX): no cross-adsorbtion
Anti-Human IgA Fluorescein Antibody generated in goat detects immunoglobulin A (alpha chain) from human. Immunoglobulin A (IgA) is an antibody that plays a critical role in mucosal immunity. IgA has two subclasses (IgA1 and IgA2) and can exist in a dimer
Clonality: Polyclonal
Concentration: 1.0 mg/mL
Isotype: Ig
Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Purity: This product was prepared from monospecific antiserum by immunoaffinity chromatography using antigens coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities.   Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Fluorescein, anti-Goat Serum, Human IgA and Human Serum.  Specificity was confirmed by ELISA minimal cross reactivity against other human heavy or light chain isotypes.
Form: Lyophilized
Formula: 20 mM K3PO4,150 mM NaCl,pH 7,2,lyophilisate,0,01% NaN3
Target: Human
Antibody Type: Secondary Antibody
Application Dilute: FLISA Dilution: 1:10,000 - 1:50,000, Flow Cytometry Dilution: 1:500 - 1:2,500, Fluorochrome Protein Value: 2.1, IF Microscopy Dilution: 1:1,000 - 1:5,000
Application Notes: Anti-Human IgA Fluorescein Antibody is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.